SARS-CoV-2 Glycosylation Profiling Service Now Available at CD BioGlyco
CD BioGlyco, a biotechnology company that offers a full range of glycobiology-related products, analysis, custom synthesis, and design to help advance glycobiology research, now provides customers with comprehensive and accurate viral glycomics information to speed up the development of vaccines and other therapeutic agents during this COVID-19 pandemic.
The US FDA has approved Pfizer and Moderna's two vaccines for sale in the US market. The scientific community is still trying to understand the virus in many ways and compile useful data. The virus uses the spike protein (S protein) to bind angiotensin-converting enzyme 2 (ACE-2) to cause infection. S protein is a highly glycosylated protein with 22 N-linked and 3 O-linked glycosylation sites. It is a key protein that affects virus infection and vaccine preparation. Therefore, it has become the focus of attention in academia and industry.
To help scientists around the world better study SARS-CoV-2, CD BioGlyco integrates its most advanced technology platforms and doe its best to promote coronavirus research. The following services are now available at CD BioGlyco for customers to choose from:
*Gene sequence of SARS-CoV-2 related proteins, including spike protein, nucleocapsid protein, papain-like protease, 3CL protease, and various receptors in host cells and other related proteins.
*A variety of glycoengineered expression systems, covering HEK293, CHO, BHK, SF21, etc., to express SARS-CoV-2 related proteins based on customers' needs.
*Comprehensive glycomics analysis platform to systematically analyze the coronavirus-related glycoproteins of interest, including glycosylation profiling, comparative characterization (changes in the propagation process and the comparison with the glycosylation characteristics of SARS-CoV, etc.), to provide the necessary basis for vaccine development.
* Lectin-based development services
According to the official speaker from CD BioGlyco, their service can be utilized for vaccine development, detection kit development, virology research, tools development for microarray, immunoassay, and virus purification from whole blood, and development of biomarkers to predict disease severity.
“We are committed to developing various technology platforms to help scientists around the world to explore the coronavirus and promote the global vaccine development process. With our professional teams and ultra-high precision instruments, we are confident to provide high-quality viral glycomics service to you all.” commented Anna, one of the marketing staff at CD BioGlyco.
To know more about the SARS-CoV-2 Glycosylation Profiling service at CD BioGlyco, please visit https://www.bioglyco.com/sars-cov-2-glycosylation-profiling.html.